Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
|Articles|April 24, 2020
COVID-19: What Lies Ahead in Mental Health?
Author(s)Michelle Riba, MD, MS, DFAPA, FAPM
Michelle Riba, MD, shares her thoughts on the days ahead.
Advertisement
Patients with depression, anxiety, and other mental health problems are going to need us more ever in the days ahead. Dr Riba is Professor and Associate Chair, University of Michigan Department of Psychiatry; Associate Director, University of Michigan Comprehensive Depression Center; and Deputy Editor in Chief Emeritus, Psychiatric Times. University of Michigan Department of Psychiatry has an excellent resources page on its website:
Advertisement
Related to this article
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Reframing “Treatment-Resistant” as “Difficult-To-Treat”
2
Formulations Matter: The Approval of Olanzapine Extended-Release Injectable Suspension for Schizophrenia
3
The New, Impending Adult ADHD Guidelines
4
Relief Is Not Free: A Case Study of Athlete Cannabis Use
5